Mosaic Family Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Mosaic Family Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-495	Closed	-$18K	–	258
2019 Q1	$18K	Hold	495	–	–	0.01%	441
2018 Q4	$14K	Hold	495	–	–	0.01%	453
2018 Q3	$18K	Hold	495	–	–	0.01%	444
2018 Q2	$29K	Hold	495	–	–	0.01%	386
2018 Q1	$23K	Hold	495	–	–	0.01%	414
2017 Q4	$12K	Hold	495	–	–	﹤0.01%	509
2017 Q3	$9K	Hold	495	–	–	﹤0.01%	578
2017 Q2	$8K	Hold	495	–	–	﹤0.01%	528
2017 Q1	$11K	Buy	+495	New	+$9.72K	﹤0.01%	502

Other funds holding CRSP

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Mosaic Family Wealth's CRSP Position: Q2 2019 in Review

Mosaic Family Wealth sold out of CRISPR Therapeutics (CRSP) in Q2 2019, closing a stake of 495 shares — an estimated $18K sold.

Mosaic Family Wealth first reported a position in CRSP in Q1 2017 and held it in 9 quarters. The position peaked at $29K in Q2 2018. 181 funds tracked by Wall St. Rank hold CRSP as of Q2 2019.

Mosaic Family Wealth reported no remaining CRISPR Therapeutics position as of Q2 2019 after selling out during the quarter.
Mosaic Family Wealth sold 495 CRISPR Therapeutics shares in Q2 2019, an estimated $18K.
Mosaic Family Wealth first reported a position in CRISPR Therapeutics in Q1 2017 and held it in 9 quarters.
Mosaic Family Wealth's CRISPR Therapeutics position peaked at $29K in Q2 2018.
181 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2019.

Based on Mosaic Family Wealth's 13F filing for Q2 2019, filed 12 Aug 2019.